Plunkett Research Online: Antibe Therapeutics Inc

ANTIBE THERAPEUTICS INC (ATE:TSE) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Antibe Therapeutics Inc develops and out-licenses new pharmaceuticals. Its main objective is to develop its lead compound otenaproxesul, by satisfying the requirements of the relevant drug regulatory authorities while also satisfying the commercial licensing objectives of prospective global partners.....



Antibe Therapeutics Inc
Ticker: ATE
Exchange: TSE
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 905 726-0995
Fax:
Address: 15 Prince Arthur Avenue
Toronto, ON M5R 1B2 Canada

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Contacts Description
Daniel Legault CEO/Director/President/Secretary
Alain Wilson CFO
See More
Antibe Therapeutics Inc develops and out-licenses new pharmaceuticals. Its main objective is to develop its lead compound otenaproxesul, by satisfying the requirements of the relevant drug regulatory authorities while also satisfying the commercial licensing objectives of prospective global partners.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2017 2016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: